1. ENSPRYNG® Fachinformation, www.swissmedicinfo.ch.
2. Traboulsee A et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, doubleblind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19: 402-12.
3. Yamamura T et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381: 2114-24.
4. Papadopoulos MC et al. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol 2014; 10(9): 493-506.
5. Wingerchuk DM et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6(9): 805-15.
6. Kessler RA et al. Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2016; 3: e269.
7. Oh J et al. Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int 2012; 2012: 460825.
8. Wingerchuk DM et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
9. Seok JM et al. Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life. PLoS One 2017; 12(5): e0177230.
10. Kanamori Y et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology 2011; 77: 652-8.
11. Thompson AJ et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162-73.
12. Pittock SJ et al. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann. N.Y. Acad. Sci. 2016; 1366: 20-39.
13. Lennon V et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
14. Kim HJ et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015; 84(11): 1165-73.
15. Bienia B et al. Immunotherapy of Neuromyelitis Optica. Autoimmune Dis 2013; 741490: 1-7.
16. Kuhlmann T et al. Diagnosis of inflammatory demyelination in biopsy specimens: a practical approach. Acta Neuropathol 2008; 115(3): 275-87.
17. Wingerchuk DM et al. The clinical course of neuromyelitis optica (Devic‘s syndrome). Neurology 1999; 53: 1107-1118.
18. Long Y et al. Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity. Front Neurol 2017; 8: 62.
19. Chihara N et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011; 108: 3701-3706.
20. Uzawa A et al. Role of interleukin-6 in the pathogenesis of neuromyelitis optica. Clin Exp Neuroimmunol 2013; 4: 167-172.
21. Jarius S et al. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014; 176(2): 149-64.
22. Uzawa A et al. Cytokine and chemokine profiles in neuromyelitis optica significance of interleukin 6. Mult Scler 2010; 16(12): 1443-52.
23. Schett G. Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford) 2018; 57(suppl 2): ii43-ii50.
24. Igawa T et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28: 1203-07.
25. Supplementary appendix to Traboulsee A et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19: 402-12.
26. Supplementary appendix to Yamamura T et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381: 2114-2124.
27. ENSPRYNG® Patienteninformation, www.swissmedicinfo.ch

Alle hier gelisteten Referenzen können von Fachpersonen bei Roche Pharma (Schweiz) AG angefordert werden.